Ratings Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE

Equities

PLX

US74365A3095

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 11:24:48 2023-03-21 am EDT			5-day change	1st Jan Change
732.5 ^ILa	-.--%		+3.29%	+69.68%

Mar. 14	Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
Mar. 14	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PROTALIX BIOTHERAPEUTICS, INC.	+69.68%	83.58M	-
MODERNA, INC.	+25.69%	47.9B	B-
LONZA GROUP AG	+47.07%	41.42B	A
IQVIA HOLDINGS INC.	-3.46%	40.7B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B	B
BIO-TECHNE CORPORATION	+0.17%	12.15B	B+
MEDPACE HOLDINGS, INC.	+28.07%	12.14B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes